ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 687

CCP Autoantibody Positive SLE Patients Show Unique Enrichments in SLE Criteria and Autoantibody Biomarkers That Vary by Race

John Goetzinger1, Carla J. Guthridge 2, Wade DeJager 2, Eliza F. Chakravarty 3, Cristina Arriens 3, Teresa Aberle 2, Aikaterini Thanou 2, Joan T. Merrill 4 and Judith James 3, 1University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 4Okalahoma Medical Research Foundation, Oklahoma City, OK

Meeting: ACR/ARP Annual Meeting 2019

Keywords: anti-CCP antibodies and race, SLE

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: SLE – Clinical Poster I: Epidemiology & Pathogenesis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Anti-cyclic citrullinated peptide (anti-CCP) antibodies are a hallmark of RA but are widely distributed in other autoimmune diseases. Although SLE is well characterized as a complex autoimmune disease eliciting a broad spectrum of autoantibodies, the significance of CCP antibodies in SLE patients (pts) remains poorly understood. This study evaluated the prevalence of anti-CCP antibodies in pts with SLE and their associations with demographic characteristics, clinical history, and other autoantibodies.

Methods: SLE patients pts (n=499) consented for research in the Oklahoma Cohort for Rheumatic Diseases were tested for anti-CCP by ELISA. Demographic information, clinical characteristics, and autoantibody profiles were extracted from medical records. Clinical features of pts who had ever tested positive for anti-CCP antibodies were compared to those who consistently tested negative for anti-CCP antibodies. Variables were analyzed using Fisher’s exact test.

Results: In 499 pts meeting ACR classification criteria for SLE 12% (61) were anti-CCP positive. Malar rash was the only classification criterion significantly less frequent in the CCP+ SLE group (CCP+: 44% vs CCP-: 58%, p < 0.05).  Anti-nuclear antibody positivity did not vary between these groups. Anti-CCP antibodies were not more common in any racial subgroup including African American (AA), Native American (NA), and European American (EA) pts. Subsetting by race into AA, EA, and NA subgroups revealed significant enrichment of serositis criteria in the AA CCP+ subgroup compared to the CCP+ EA and CCP+ NA subgroups. In the CCP- subgroups, EA subjects were enriched for malar rash compared to the CCP- AA subgroup and enriched for photosensitivity compared to the CCP- AA and CCP- NA subgroups. The CCP- AA subgroup was significantly enriched for renal criteria compared to the CCP- EA subgroup and enriched for immunologic criteria compared to the CCP- EA and CCP- NA subgroups. In both the CCP+ and CCP- AA subgroups, discoid rash was enriched compared to the EA and NA subgroups and anti-Sm positivity was enriched compared to the EA subgroups. Among the CCP- subgroups, SS-B (La) was enriched in the NA subgroup compared to the AA subgroup and Cent B was enriched in the NA subgroup compared to the AA and EA subgroups. All RNP autoantibodies were enriched in the CCP- AA subgroup, but not the CCP+ AA subgroup.

Conclusion: Race contributes to variations in the frequency of ACR criteria and antinuclear autoantibodies which were observed between the CCP+ and CCP- SLE patients.


Disclosure: J. Goetzinger, None; C. Guthridge, None; W. DeJager, None; E. Chakravarty, None; C. Arriens, AstraZeneca, 5, BMS, 2, 5, Exagen, 2, GSK, 2, 5; T. Aberle, None; A. Thanou, Neovacs, 5; J. Merrill, Abbvie, 5, Amgen, 5, Astellas, 5, AstraZeneca, 5, BMS, 2, 5, Celgene, 5, EMD Serono, 5, GSK, 2, 5, Idorsia, 5, ILTOO, 5, Immupharma, 5, Incyte, 5, Janssen, 5, Lilly, 5, Remegen, 5, Servier, 5, Xencor, Inc., 2; J. James, Abbvie, 5, Janssen, 5, Progentec, 2, Progentec Diagnostics, Inc., 2, Xencor, 2, Xencor, Inc., 2.

To cite this abstract in AMA style:

Goetzinger J, Guthridge C, DeJager W, Chakravarty E, Arriens C, Aberle T, Thanou A, Merrill J, James J. CCP Autoantibody Positive SLE Patients Show Unique Enrichments in SLE Criteria and Autoantibody Biomarkers That Vary by Race [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/ccp-autoantibody-positive-sle-patients-show-unique-enrichments-in-sle-criteria-and-autoantibody-biomarkers-that-vary-by-race/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARP Annual Meeting 2019

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ccp-autoantibody-positive-sle-patients-show-unique-enrichments-in-sle-criteria-and-autoantibody-biomarkers-that-vary-by-race/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology